

1. Record Nr.	UNINA9910872187303321
Autore	Weiss Jeffrey N
Titolo	Clinical Trials in Stargardt Disease Treatment
Pubbl/distr/stampa	Cham : , : Springer International Publishing AG, , 2024 ©2024
ISBN	9783031588075 9783031588068
Edizione	[1st ed.]
Descrizione fisica	1 online resource (240 pages)
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Preface -- Contents -- Chapter 1: Introduction to Stargardt Disease -- Further Reading -- Chapter 2: Tables -- Chapter 3: Recruiting Studies -- Recruiting -- United States -- Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease (GARDian) -- ClinicalTrials.gov ID NCT05956626 -- United States -- Recruiting -- Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) -- ClinicalTrials.gov ID NCT02402660 -- United States -- Recruiting -- Rod- and Cone-Mediated Function in Retinal Disease -- ClinicalTrials.gov ID NCT02617966 -- United States -- Recruiting -- Stargardt-Like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4 -- ClinicalTrials.gov ID NCT04591483 -- United States -- Recruiting -- Oral Metformin for Treatment of ABCA4 Retinopathy -- ClinicalTrials.gov ID NCT04545736 -- United States -- Recruiting -- Genotype-Phenotype Study of Patients with Plaquenil-Induced Retinal Toxicity, with Evaluation of the ABCA4 Gene -- ClinicalTrials.gov ID NCT01145196 -- United States -- Recruiting -- Inherited Retinal Degenerative Disease Registry (MRTR) -- ClinicalTrials.gov ID NCT02435940 -- United States -- Recruiting -- Stem Cell Ophthalmology Treatment Study II (SCOTS2) -- ClinicalTrials.gov ID NCT03011541 -- Spain -- Recruiting -- Structural and Functional Characterization of Rare Ocular Diseases (RADIS) -- ClinicalTrials.gov ID NCT05258032 -- Switzerland -- Recruiting -- Function and Imaging

Assessments for G1961E-associated Stargardt Disease (FIRSTORBIT) -- ClinicalTrials.gov ID NCT05674058 -- Chapter 4: Enrolling by Invitation Studies -- United States -- Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study (SUSTAIN) -- ClinicalTrials.gov ID NCT06048185 -- United States -- Enrolling by Invitation.

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) -- ClinicalTrials.gov ID NCT04239625 -- Chapter 5: Active, Not Recruiting Studies -- United States -- Phase I/II Follow-up Study of SAR422459 in Patients with Stargardt's Macular Degeneration -- ClinicalTrials.gov ID NCT01736592 -- United States -- Active, Not Recruiting -- Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects with Stargardt Disease (STARLIGHT) -- ClinicalTrials.gov ID NCT05417126 -- United States -- Active, Not Recruiting -- Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects with STGD1 (DRAGON) -- ClinicalTrials.gov ID NCT05244304 -- United States -- Active, Not Recruiting -- Zimura Compared to Sham in Patients with Autosomal Recessive Stargardt Disease (STGD1) -- ClinicalTrials.gov ID NCT03364153 -- United States -- Active, Not Recruiting -- Natural History of Eye Diseases Related to ABCA4 Mutations -- ClinicalTrials.gov ID NCT01736293 -- Australia -- Active, Not Recruiting -- This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects with Stargardt Disease -- ClinicalTrials.gov ID NCT05266014 -- Chapter 6: Completed Studies -- United States -- The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy (ProgStar-4) -- ClinicalTrials.gov ID NCT02410122 -- No Results Posted -- United States -- Completed -- Safety and Efficacy of Emixustat in Stargardt Disease (SeaSTAR) -- ClinicalTrials.gov ID NCT03772665 -- Results -- Outcome Measures -- United States -- Completed.

A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies (ProgSTAR) -- ClinicalTrials.gov ID NCT01977846 -- Results -- Outcome Measures -- United States -- Completed -- Study of STG-001 in Subjects with Stargardt Disease -- ClinicalTrials.gov ID NCT04489511 -- United States -- Completed -- DHA Supplementation in Patients With STGD3 -- ClinicalTrials.gov ID NCT00420602 -- No Results Posted -- United States -- Completed -- Pharmacodynamic Study of Emixustat Hydrochloride in Subjects with Macular Atrophy Secondary to Stargardt Disease -- ClinicalTrials.gov ID NCT03033108 -- Results -- Outcome Measures -- United States -- Completed -- Microcurrent Stimulation to Treat Macular Degeneration -- ClinicalTrials.gov ID NCT01790958 -- United States -- Completed -- Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy -- ClinicalTrials.gov ID NCT00346853 -- United States -- Completed -- Effect of DHA Supplements on Macular Function in Patients with Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy -- ClinicalTrials.gov ID NCT00060749 -- United States -- Completed -- Long-Term Follow-Up of Subretinal Transplantation of hESC-Derived RPE Cells in Stargardt Macular Dystrophy Patients -- ClinicalTrials.gov ID NCT02445612 -- United States -- Completed -- Subretinal Transplantation of hESC-Derived RPE(MA09-hRPE)Cells in Patients with Stargardt's Macular Dystrophy -- ClinicalTrials.gov ID NCT01345006 -- Brazil -- Completed -- Stem Cell Therapy for Outer Retinal Degenerations -- ClinicalTrials.gov ID NCT02903576 -- China -- Completed -- The Effect of Duration Between Sessions

on Microperimetric Biofeedback Training in Patients with Maculopathies -- ClinicalTrials.gov ID NCT05904444 -- Columbia -- Completed -- Efficacy of Acupuncture in Macular Diseases (AMAD) -- ClinicalTrials.gov ID NCT02255981 -- Results. Outcome Measures -- Europe -- Completed -- Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (MADEOS) -- ClinicalTrials.gov ID NCT03297515 -- Europe -- Completed -- Pupil Dynamics and Color Vision for the Detection of Eye Diseases (PupDyn) -- ClinicalTrials.gov ID NCT04909398 -- United Kingdom -- Completed -- A Follow-Up Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients with Stargardt's Macular Dystrophy (SMD) -- ClinicalTrials.gov ID NCT02941991 -- United Kingdom -- Completed -- Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients with Stargardt's Macular Dystrophy (SMD) -- ClinicalTrials.gov ID NCT01469832 -- No Location -- Completed -- Phase 1 Safety Study of ALK-001 in Healthy Volunteers -- ClinicalTrials.gov ID NCT02230228 -- Chapter 7: Terminated Studies -- United States -- Phase I/IIA Study of SAR422459 in Participants with Stargardt's Macular Degeneration -- ClinicalTrials.gov ID NCT01367444 -- Results -- Outcome Measures -- United States -- Terminated -- Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease -- ClinicalTrials.gov ID NCT01676766 -- United States -- Terminated -- Oxidative Stress in Stargardt Disease, Age-Related Macular Degeneration, and Diabetic Retinopathy -- ClinicalTrials.gov ID NCT02875704 -- Chapter 8: Unknown Status Studies -- China -- Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell-Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases -- ClinicalTrials.gov ID NCT02749734 -- Europe -- Unknown Status -- Saffron Supplementation in Stargardt's Disease (STARSAF02). ClinicalTrials.gov ID NCT01278277 -- Europe -- Unknown Status -- Stem Cells Therapy in Degenerative Diseases of the Retina -- ClinicalTrials.gov ID NCT03772938 -- Korea -- Unknown Status -- Safety and Tolerability of MA09-hRPE Cells in Patients with Stargardt's Macular Dystrophy (SMD) -- ClinicalTrials.gov ID NCT01625559 -- United Kingdom -- Unknown Status -- Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those with Severely Reduced Vision -- ClinicalTrials.gov ID NCT04281732 -- Index.
